22994 0 32580 1 23443 2 22994 0 32580 1 23443 2 41153 0 41150 1 41123 2 41153 0 41150 1 41123 2

Last Updated: 02/12/2024

RTSS (Efficacy of GSK Biologicals’ candidate malaria vaccine against malaria disease caused by Plasmodium falciparum infection in infants and children in Africa)

Objectives

The objectives of this project are to assess the following reagrding RTSS vaccine:

  1. Efficacy against severe malaria disease.
  2. Efficacy against incidence of severe anaemia and malaria hospitalization.
  3. Efficacy; duration of efficacy of a primary course.
  4. Efficacy; the role of booster dose.
  5. Efficacy under different transmission settings.
  6. Efficacy agaisnt secondary case definition of clinical malaria disease.
  7. Safety of a primary course.
  8. Safety of a booster dose.
  9. Immunogenicity of a primary course.
  10. Immunogenicity of a booster dose.
Principal Investigators / Focal Persons

John P. Lusingu

Study Design

Randomized Double-blind multi-centre clinical trial

Thematic Categories

Impact of Interventions
Vaccines

Date

Jan 2009 — Dec 2013

Total Project Funding

$7.41M

Project Site

Tanzania

SHARE
SHARE